BETHLEHEM, Pa., June 17 /PRNewswire/ -- Saladax Biomedical, a company specializing in chemotherapy therapeutic drug monitoring, today announced CE mark registration in the European Union (EU) for its 5-FU Personalized Chemotherapy Management (PCM(R)) assay on the Olympus AU400 Clinical Chemistry Analyzer. For European oncologists who prescribe 5-fluorouracil (5-FU) continuous infusion regimens alone or in combination (e.g., FOLFOX and FOLFIRI) for colorectal, stomach, breast, and pancreatic cancers, this simple, evidence-based blood test will show patients' actual plasma 5-FU levels for individualized dosing.
"Until now, a simple, rapid, and cost-effective 5-FU measurement tool that can be easily integrated into day-to-day practice has not been readily available. As a result, colorectal cancer patients receive chemotherapy based on their height and weight, with no monitoring system in place to allow oncologists to correlate dose with clinical patient response on an ongoing basis," said Salvatore Salamone, Ph.D., CEO of Saladax Biomedical. "Access to this simple blood test will arm oncologists with the ability to individualize 5-FU dosing to ensure patients receive the optimal benefit from their treatment."
Recently, results from a Phase III randomized study compared colorectal
cancer patients who were dosed with 5-FU based on the current standard
dosing method (body surface area or BSA) with patients whose dose was
adjusted based on the actual concentration of 5-FU in the patients' blood
plasma. The study, which was published in the May issue of the Journal of
Clinical Oncology (JCO) concluded:
-- Response rates among monitored patients doubled(i)
-- Two-year overall survival improved by 48 percent(i)
-- Toxic side effects were significantly lower(i)
-- Only 25 percent of BSA dosed patients were in the target range to
receive the optimal therapeutic benefit(i)
- 58 percent of patients were found to be under-dosed and had doses
- 17 percent were found to be over-dosed, increasing the risk of severe
"The availability of the 5-FU PCM assay will give oncologists in the EU a powerful, cost-effective tool in the battle against colorectal cancer," said Erick Gamelin, M.D., Ph.D. director of the Paul Papin Cancer Center in Angers, France and primary investigator of the Phase III JCO study. "Our Phase III study demonstrates that the majority of patients are either over-dosed or in most cases, under-dosed. Personalized 5-FU dosing allows us to substantially reduce severe toxicity while improving patient quality of life and treatment outcomes."
About Colorectal Cancer
Colorectal cancer is a worldwide public health problem, with more than 940,000 new cases diagnosed each year, resulting in approximately 500,000 deaths annually.(ii) In the U.S., it is the third leading cause of cancer mortality, and in 2008, nearly 50,000 deaths will be attributed to this disease.(iii) Its incidence rate is strongly correlated with age. Data from industrialized countries demonstrate that the incidence of colorectal cancer rises three-fold between the ages of 60 and 80 years.(i)
Saladax Biomedical is pioneering the development of novel, rapid, and
cost-effective immunoassays that will enable routine blood-level monitoring
of anti-cancer drugs to become the standard of care in treating cancer
patients. With Personalized Chemotherapy Management (PCM), oncologists will
be able to adjust the administered dose based on each patient's individual
drug level, leading to reduced toxicity, improved outcome and lower cancer
care costs. Saladax is headquartered at the business incubator of the Ben
Franklin Technology Partners (BFTP) of Northeastern Pennsylvania on the
campus of Lehigh University in Bethlehem. The 5-FU PCM test will be
available to U.S. clinicians later this year through a major reference
(i) Gamelin, E, Delva, R, Jacob, J, et al: "Individual fluorouracil dose
adjustment based on pharmacokinetic follow-up compared with
conventional dosage: Results of a multicenter randomized trial of
patients with metastatic colorectal cancer." J. Clin Oncol 13:2099-
(ii) World Health Organization, "World Cancer Report." April 3, 2003,
(iii) American Cancer Society, "What are the Key Statistics for Colorectal Cancer?", March 5, 2008, http://www.cancer.org/docroot/cri/content/cri_2_4_1x_what_are_the_key_stati sti cs_for_colon_and_rectum_cancer.asp (April 22, 2008).
|SOURCE Saladax Biomedical|
Copyright©2008 PR Newswire.
All rights reserved